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Background:We aimed to characterise the genetic determinants and context of twomeropenem-resistant clin-
ical isolates of Acinetobacter baumannii isolated from children hospitalised with bloodstream infections in Dar
es Salaam, Tanzania.
Methods: Antimicrobial susceptibility was determined by disc diffusion E-test and broth microdilution. Genomes
were completed using a hybrid assembly of Illumina and Oxford Nanopore Technologies sequencing reads and
characterisation of the genetic context of resistance genes, multi-locus sequence types (STs) and phylogenetic
analysis was determined bioinformatically.
Results: Twelve A. baumanniiwere isolated from 2226 blood cultures, two of which were meropenem-resistant.
The two meropenem-resistant isolates, belonging to distinct STs, ST374 and ST239, were found to harbour
blaNDM-1, which was chromosomally located in isolate DT0544 and plasmid-located in isolate DT01139. The
genetic environment of blaNDM-1 shows the association of insertion sequence ISAba125 with blaNDM-1 in both
isolates. Both isolates also harboured genes conferring resistance to other β-lactams, aminoglycosides and
cotrimoxazole.
Conclusions: This is the first report of New Delhi metallo-β-lactamase-producing isolates of A. baumannii from
Tanzania. The genetic context of blaNDM-1 provides further evidence of the importance of ISAba125 in the spread
of blaNDM-1 in A. baumannii. Local surveillance should be strengthened to keep clinicians updated on the incidence
of these and other multidrug-resistant and difficult-to-treat bacteria.
Keywords: Acinetobacter baumannii, antimicrobial resistance mechanisms, bloodstream infections, New Delhi metallo-β-
lactamase 1, Tanzania
Introduction
Acinetobacter baumannii is a Gram-negative, opportunistic
pathogen that can cause infections of multiple body sites,
including the bloodstream, lungs and urinary tract.1–3 Acineto-
bacter baumannii infections are often difficult to treat because
of intrinsic and acquired resistance mechanisms and are asso-
ciated with poor clinical outcomes.2 Carbapenems are indis-
pensable last-resort antibiotics for severe infections caused
by multidrug-resistant bacteria, although they are expensive
and largely unavailable in low-income settings. The clinically
important β-lactamase New Delhi metallo-β-lactamase 1
(NDM-1), which confers resistance to carbapenems, was first
reported in A. baumannii in India4 and NDM-1-producing A.
baumannii have since been reported from northern and eastern
Africa (Algeria, Libya, Egypt, Tunisia, Kenya and Ethiopia) and
South Africa.5–11 To the best of our knowledge, NDM-1-producing
A. baumannii has not yet been reported in Tanzania. As blaNDM-1-
carrying bacteria are often multidrug-resistant, infections due
to NDM-1-producing A. baumannii may increase the risk of poor
clinical outcomes due to a lack of therapeutic options. Therefore,
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there is a need to report the detection, spread and molecular
epidemiology of multi-drug resistant A. baumannii-producing
NDM-1 in resource-limited settings.
In a large-scale study to determine the causes of bloodstream
infections in children in Dar es Salaam, Tanzania,12 we detected
two carbapenem-resistant isolates of A. baumannii in blood cul-
tures from febrile Tanzanian children. This study was conducted
to determine the mechanisms responsible for carbapenem resis-
tance. Using whole genome sequencing (WGS) we predicted the
resistance genes present in the two A. baumannii isolates and
compared them with the corresponding phenotypic resistance.
Furthermore, we characterised the genetic context of blaNDM-1,
determined the sequence types (STs) of both isolates and placed
them within the phylogenetic context of other A. baumannii-
carrying blaNDM-1 previously sequenced.
Materials and methods
Study population, bacteria isolation and identification
A cross-sectional study was conducted from March 2017 to
July 2018.12 We obtained blood cultures from 2226 children
aged <5 y hospitalised because of fever at Amana, Temeke and
Mwananyamala Regional hospitals and Muhimbili National Hos-
pital (MNH), Dar es Salaam, Tanzania. Blood was cultured using
BACTEC FX40 system (Becton-Dickinson, Sparks, MD, USA) and
the bacteria isolated were identified by Matrix-Assisted Laser
Desorption/Ionization-Time Of Flight (MALDI-TOF) mass spec-
trometry (MS), using the Microflex LT instrument and MALDI Bio-
typer 3.1 software (Bruker Daltonics, Bremen, Germany).
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by disk diffu-
sion on Mueller-Hinton agar plates at 35°C and incubated for
16–18 h according to Clinical and Laboratory Standards
Institute (CLSI) guidelines.13 Antibiotic discs included were
piperacillin/tazobactam (TZP), ceftazidime, cefotaxime,
meropenem, imipenem, ciprofloxacin, sulphamethoxa-
zole/trimethoprim, gentamicin tetracycline and doxycycline
(Oxoid, UK). The minimum inhibitory concentrations (MICs)
for TZP, ceftazidime, cefotaxime, meropenem, imipenem,
ciprofloxacin, sulphamethoxazole/trimethoprim, gentam-
icin tetracycline and doxycycline were determined by E-
test (bioMérieux,Marcy-I´Etoile, France) following CLSI guidelines.
The MIC of colistin was determined by broth microdilution in
cation-adjusted Mueller-Hinton broth according to CLSI guide-
lines.
WGS and analysis
WGS was performed using HiSeq X10 (Illumina, San Diego, CA,
USA) by Microbes NG (UK), who also performed quality filtering
and sequencing read trimming and MinION (Oxford Nanopore
Technologies [ONT], Oxford, UK) platforms. ONT long reads
were de-multiplexed with Porechop (v. 0.2.4; https://github.com/
rrwick/Porechop) and filtered with a quality score of 30 using Filt-
long (v. 0.2.0; https://github.com/rrwick/Filtlong). Long and short
read sequences were assembled using Unicycler (v. 0.4.8.0)14,15
and the genome was annotated with Prokka (v. 1.14.6).16
The blaNDM-1-carrying plasmid from isolate DT01139 and
upstream and downstream of blaNDM-1 in the chromosome of
isolate DT0544 were annotated manually using a combination
of Prokka (v. 1.14.6)16 BLAST (v. 2.11.0),17 ResFinder (v. 4.1),18
UniProt and MobileElementFinder (v. 1.0.3)18 in SnapGene (v.
3.3.4) from GSL Biotech (available at snapgene.com). Compari-
son of the annotated plasmid from DT01139 with other blaNDM-1-
carrying plasmids from A. baumannii was performed using BRIG
(v. 0.95).19 Comparison of upstream and downstream of blaNDM-1
for the isolate DT01139 and DT0544 was produced using EasyFig
(v. 2.2.2).20
Identification of resistance genes and multi-locus
sequence typing
Prediction of antimicrobial resistance genes and multi-locus
sequence typing (MLST) were carried out using ResFinder
(v. 4.1)21,22 and MLST (v. 2.19.0; https://github.com/tseemann/
mlst), which uses the PubMLST database (https://pubmlst.org).23
Phylogenetic analysis
A single nucleotide polymorphism (SNP)-based phylogenetic
tree was created using conserved signature inserts phylogeny
server (v. 1.4),24 comparing the two isolates in this study to
27 published blaNDM-1-carrying A. baumannii WGS using default
parameters. Acinetobacter baumannii ab736 [accession number
NZ_CP015121] was used as the reference genome for the phy-
logenetic tree. The phylogenetic tree was annotated using the
Interactive Tree of Life (v. 5.6.3).25
Results
Characteristics of the two patients
with A. baumannii-carrying NDM-1 gene
In total, 12 A. baumannii isolates were identified, two of which
were found to be meropenem-resistant by antimicrobial suscep-
tibility testing and were designated as DT0544 and DT01139. The
two meropenem-resistant A. baumannii isolates were obtained
from blood cultures of neonates. Isolate DT0544 was obtained
from a 4-d-old male neonate, admitted as a referral patient from
a regional hospital to MNH in October 2017 with a history of
fever and convulsions. This patient received ceftriaxone and gen-
tamicin on admission but died the next day. Isolate DT01139
was obtained from a 3-d-old female neonate, admitted from
a healthcare centre to Amana Regional Hospital in November
2017 with a history of fever. This patient received amoxicillin-
clavulanate and gentamicin on admission, but due to her wors-
ening condition the treatment changed to ceftriaxone and gen-
tamicin. After 7 d she was transferred to another hospital and
was lost to follow-up.
Antimicrobial susceptibility testing results
Susceptibility testing results identified the two A. baumannii iso-
lates were resistant to imipenem and meropenem as well as
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Table 1. Antimicrobial susceptibility results and acquired resistance genes of the two A. baumannii
Disc diffusion MIC (E-test) μg/ml Acquired resistance genes
Antimicrobial class Antimicrobial agent DT0544 DT01139 DT0544 DT01139 DT0544 DT01139
Fluoroquinolone Ciprofloxacin S (23 mm) S (27 mm) 0.094 0.064 none none










Ceftazidime R (0 mm) R (0 mm) >256 >256
Cefotaxime R (0 mm) R (0 mm) 32 32
Meropenem R (14 mm) R (16mm) 4 4
Imipenem R (11 mm) R (16 mm) 32 8
Folate antagonist Sulphamethoxazole/trimethoprim R (0 mm) R (0 mm) >256 4 sul2 and
dfrA1
sul2
Tetracyclines Tetracycline S (19 mm) S (21 mm) 4 4 none none
Doxycycline S (21 mm) S (24 mm) 0.5 0.5







Polymyxin Colistin NA NA 16* 16* none none
Note: NA, test not applicable for that antimicrobial agent; * MIC tested by broth microdilution.
patients, and were susceptible to ciprofloxacin and tetracyclines
(Table 1). Both isolates were resistant to imipenem with a MIC of
32 μg/ml (DT0544) and 8 μg/ml (DT01139). Resistance to gen-
tamicin and colistin was also identified in two isolates with a MIC
towards gentamicin of 128 and24μg/ml for DT01139andDT054,
respectively, while both isolates had a MIC of 16 μg/ml towards
colistin.
WGS results
Isolate DT0544 contained two plasmids of approximately 55 and
4 Kb in size, while isolate DT01139 contained three plasmids of
97, 64 and 10 Kb in size. blaNDM-1 was predicted to be present
in both isolates; the β-lactamase was chromosomally located in
isolate DT0544 while for DT01139 it was plasmid-located (Fig-
ure 1A,1B). The β-lactamases blaADC-25 and blaCARB-16 were also
present in both isolates, while blaOXA-259, belonging to blaOXA-51
type, was present in DT0544; and DT01139 contained blaOXA-51.
Several other resistance genes were predicted in the genome of
DT0544: aadA1aph (3′′)-Iaand ant (2′′)-Ia (aminoglycosides), sul2
(sulphonamides) and dfrA1 (trimethoprim), all located on a 55
Kb plasmid, while DT01139 was predicted to contain aac (3)-IId
and aph (3′) VI (aminoglycosides), sul2 (sulphonamides) and floR
(phenicol), all located on the 64 Kb plasmid with blaNDM-1. Pre-
dicted resistance genes by WGS were supported by and corre-
sponded to phenotypic susceptibility. However, it is worth noting
that no acquired mcr gene conferring resistance to colistin was
detected.
Genetic environment of blaNDM-1 gene
blaNDM-1 is located on a composite transposon, Tn125, in DT0544
flanked by two copies of the insertion sequence (IS) ISAba125 ori-
entated in the same direction (Figure 1A). However, in DT01139,
only one copy of ISAba125 is present upstream and the
approximately 20 kb region containing blaNDM-1 and other resis-
tance genes (for aminoglycosides, sulphonamides and pheni-
col) is flanked by two copies of ISAba14 (Figure 1A). Figure 1B
shows comparison of the blaNDM-1-carrying plasmid on isolate
DT01139 with other reported NDM-1-carrying plasmids (pAB17,
pAbNDM-1, pAR_0088, pIEC383, pM131 and pNDM-GJ0; see Sup-
plementary Table 1 for accession numbers) of A. baumannii.
The blaNDM-1-harbouring plasmid from the isolate DT01139 differs
from the other plasmids compared, but has shown some areas of
similarity upstream and downstream of blaNDM-1.
STs and phylogenetic analysis
Using the Pasteur MLST scheme, the two isolates were found to
belong to two distinct STs, ST374 (DT0544) and ST 239 (DT01139).
Figure 1C is a whole genome SNP-based phylogenetic tree con-
taining the two isolates from this study and 27 other A. bauman-
nii containing blaNDM-1 (see Supplementary Table 1 for accession
numbers). We found a clonal diversity among NDM-1-producing
A. baumannii isolates fromdifferent parts of theworld and isolate
DT0544 from this study was closely related to strain R2090 from
Egypt.
Discussion
While NDM-1-producing A. baumannii has been reported from
other sub-Saharan African countries (e.g. Kenya,8 Ethiopia9 and
South Africa),10 this is the first time it has been reported
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Figure 1. The genetic environment of the blaNDM-1 and phylogenetic context of DT0544 and DT01139. (A) Genetic context of blaNDM-1 from DT01139
and DT0544 compared with blaNDM-1 from A. baumanniiwith a similar genetic arrangement. Arrows represent insertion sequences (yellow), antimicro-
bial resistance genes (blue), blaNDM-1 (black) and other resistant genes (orange). (B) Annotation of the 97 Kb plasmid-containing blaNDM-1 fromDT01139
comparison with other blaNDM-1-containing plasmids from A. baumannii. Arrows represent hypothetical proteins (grey), insertion sequences and trans-
posable elements (purple), antimicrobial resistance genes (blue), blaNDM-1 (black), type IV secretion system genes (green) and other genes (red).
(C) Whole genome single nucleotide polymorphism (SNP)-based phylogenetic tree compared with other blaNDM-1 A. baumannii. Country of isolation is
in brackets and isolates for this study, DT01139 and DT0544, are highlighted in yellow.
where NDM-1-producing A. baumannii originated from samples
obtained from axilla, abscesses, peritoneal swabs and the uri-
nary tract,8–10 our isolates originated from bloodstream infec-
tions, emphasising their clinical importance. These findings are
of significant public health importance as they show that there
is ongoing dissemination of NDM-1-type resistance in an African
setting.
The fact that the two neonates, only 3 and 4 d old, were
transferred from a health centre and a regional hospital, respec-
tively, and that the blaNDM-1-producing A. baumannii isolates
were obtained from blood cultures taken on admission at the
study hospital, raises concern that they may have acquired these
multidrug-resistant bacteria locally at health facilities serving
local communities.
The two isolates were susceptible only to ciprofloxacin
and tetracyclines, but resistant to all other antibiotics tested.
Evidence-based guidelines are vital for the acute management
of severe systemic infections before microbiological results are
ready. In sub-Saharan Africa, empirical treatment guidelines
are even more important, as microbiological laboratory services
are impeded by limited infrastructure capacity and funding to
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testing. Only major referral hospitals have the capacity to iden-
tify specific multidrug-resistant problematic bacteria such as
carbapenemase-producing Gram-negatives. The empiric treat-
ment protocol that was used to treat the two patients did not
include the antibiotics to which the isolates were sensitive, hence
the patients did not receive appropriate treatment, and we know
at least one of them died. This highlights the importance of intro-
ducing and strengthening antimicrobial resistance surveillance
programmes.
Differing antibiograms, resistance gene profiles and STs show
the isolates are not clonal. Furthermore, blaNDM-1 was carried on a
chromosomally located composite transposon Tn125 in one iso-
late and on a plasmid with only one ISAba125 in the other and
therefore are not representative of an outbreak.
The two neonates and their parents had no history of travel-
ling outside the country and the travel history of their healthcare
providers is unknown. Therefore, to understand in depth the ori-
gins and extent of NDM-1-producing A. baumannii in the region
there is a need for a comprehensive surveillance programme
within the healthcare system in the country.
This study has shown further evidence of diversity among
the NDM-1-producing A. baumannii in different parts of the
world, for example, the two isolates belong to ST374 and ST239
(Pasteur MLST), while in the neighbouring countries Kenya and
Ethiopia, NDM-1-producing A. baumannii belong to ST25 and
ST957, respectively, and from Tunisia in northern Africa they
belong to ST85.7–9 In European countries (Switzerland, Slovenia,
Germany, France and Belgium), the NDM-1-producing isolates
of A. baumannii were reported to belong to ST1, ST25, ST85 and
ST92.5,26 While ST1, ST25 and ST85 are now widely reported
throughout the globe, the two STs (374 and 239) in our study
have been rarely reported. Non-NDM-1-producing A. baumannii
ST374 isolates have previously been isolated from a wound swab
in Kilimanjaro, the northern region of Tanzania (strain KCRI-49
with [accession number GCA_900406775.1]) and from respira-
tory tract infection in Brazil (strain Ac56 with [accession number
WP1Q00000000]). There is one previously reported ST239 A.
baumannii isolate, H33 from Japan (https://pubmlst.org/bigsdb?
page=info&db=pubmlst_abaumannii_isolates&id=1695) and
other ST239 have been isolated from pets in France.27 In addition
to a wide variety of STs among NDM-1-producing A. baumannii,
the phylogenetic analysis (Figure 1C) also showed that the
strains of A. baumannii-producing NDM-1 are not clonally related
between different countries and within one country (e.g. two
strains in the current study and three strains from Ethiopia
and Thailand). This shows that the spread of NDM-1-producing
A. baumannii in Africa is not clonal and likely results from the
spread of the NDM-1 gene itself, as reported in Europe.26 A similar
situation has been recently reported with NDM-1 in Klebsiella
pneumoniae.28
The genetic environment of blaNDM-1 has previously been
reported to be on the composite transposon Tn125, flanked
by ISAba125.29,30 In A. baumannii DT0544, Tn125 harbouring
blaNDM-1 is 100% identical to that found in A. baumannii VB473
[accession number CP050388] isolated from human sputum in
India and is up to 99% identical to many other copies of Tn125
from various Acinetobacter spp.30 and other bacteria, including
Escherichia coli and K. pneumoniae. The similar genetic organ-
isation of blaNDM-1 on a Tn125 in most A. baumannii and other
Acinetobacter spp. is due to the Tn125-linked mobility of
blaNDM-1.31 In A. baumannii, DT01139 blaNDM-1 is associated with
an upstream copy of ISAba125 in a more complex, plasmid-
located arrangement flanked by ISAba14 (Figure 1B).
This is the first report of NDM-1-producing A. baumannii iso-
lated from neonates with bloodstream infections from Tanzania.
The genetic context of blaNDM-1 provides further evidence of the
importance of ISAba125 in the spread of blaNDM-1 in A. bauman-
nii. These findings shed light on the epidemiology of carbapenem
resistance in Africa and calls for continued and strength-
ened surveillance to guide clinicians treating severe bacterial
infections.
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